14th Jul 2009 08:00
Cyprotex PLC
("Cyprotex" or the "Company")
AGM Statement
Momentum maintained in current year
Cyprotex (AIM:CRX), the drug discovery technology and information company, will hold its Annual General meeting today. At that meeting, Steve Harris, Chairman, will make the following comments:
"2008 was a highly significant year for Cyprotex; we delivered a maiden profit, grew revenues 43% to £5.2m and were cash generative. The Company has continued to perform well in the current year. It has been an uncertain period for some customers and competitors alike in our industry and we have experienced reduced orders from a small number of important customers as a result. However, this has been offset by increased demand from other customers and for new products, reflecting the ongoing investment in new technology and equipment."
"Overall, performance remains ahead of the same period last year. Taking into account the historic seasonality of the business, which sees around 55% of revenues and a much larger proportion of profits generated in the second half, we remain confident in the outlook for the full year. The Company remains cash generative."
Cyprotex expects to announce its interim results for the six months to 30 June 2009 on the 12 August 2009.
For further information:
|
Cyprotex PLC |
Tel: +44 (0) 1625 505 100 |
|
|
Dr Anthony Baxter, Chief Executive Officer John Dootson, Chief Financial Officer |
||
|
www.cyprotex.com |
||
|
Noble & Company |
Tel: +44 (0) 20 7763 2200 |
|
|
John Llewellyn-Lloyd |
||
|
Sam Reynolds |
||
|
www.noblegp.com |
||
|
Financial Dynamics |
Tel: +44 (0) 20 7831 3113 |
|
|
Ben Brewerton / Ben Atwell / John Dineen |
||
|
www.fd.com |
||
Related Shares:
CRX.L